Optimal Antiplatelet Regimen in “Bi-Risk” ACS?
Among "bi-risk" patients with acute coronary syndrome (ACS) who received a stent and completed 9-12 months of dual antiplatelet therapy ...
Among "bi-risk" patients with acute coronary syndrome (ACS) who received a stent and completed 9-12 months of dual antiplatelet therapy ...
AMSTERDAM — Dropping aspirin and using low-dose prasugrel (Effient) alone in the initial month of treatment after percutaneous coronary intervention ...
MUNICH — Anticoagulation using apixaban (Eliquis) offers no benefit over aspirin in patients with embolic stroke of undetermined source (ESUS) ...
Over-the-scope clips (OTSC) may prevent further bleeding more so than standard endoscopic treatment when used as primary treatment in patients with ...
Performing endovascular thrombectomy in patients with an ischemic stroke having a large ischemic core has been found to be beneficial ...
The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca) for relapsed or refractory mantle cell ...
Replacing dual-antiplatelet therapy (DAPT) with clopidogrel alone 1 month after percutaneous intervention (PCI) offers a lower risk of bleeding with ...
© Pharma News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.
© 2022 Pharma News Hubb All rights reserved.